SlideShare ist ein Scribd-Unternehmen logo
1 von 4
Downloaden Sie, um offline zu lesen
OFFICE OF THE DEPUTY DIRECTOR
VIROLOGY
NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES
1 Modderfontein Road, Sandringham, 2031
Tel: +27 (0)11 386-6328 Fax: +27 (0)11 386-6411
Validation of the Q – Preven HIV 1 + 2 DBS Immunoenzyme Kit
Summary:
The Q-Preven HIV 1+2 DBS kit is an enzyme immunosorbent assay (ELISA) for the detection of
antibodies against HIV 1, HIV 2 and HIV 1 subtype O in Dried Blood Spot Specimens (DBS). The
kit consists of the following items: Dried Blood Spot Collection Kit which consists of the filter paper
and lancet; and the Test Kit which consists of ELISA Microplate and ELISA reagents required to
conduct an ELISA test. Supplies with the kit are negative and positive dried blood spot controls.
The following steps were completed during the validation:
Replicate testing using Kit Controls:
The negative DBS control and the positive DBS control from the Q-Preven test kit was tested 8
times in the same run and the results analyzed. All the controls passed validation and all controls
run as samples were within acceptable ranges i.e. the negative controls were negative and the
positive controls were positive.
Precision and Accuracy Testing:
Three negative and three positive controls taken from the Q-Preven test kit were tested over a
period of five consecutive days. The same operator tested the controls over the five day period and
the same plate washer, plate incubator and plate reader was used during the testing. The results of
the precision and accuracy testing are listed in Table 1 below:
Table 1
ID Day 1 -
Ratio
Day 2 -
Ratio
Day 3 -
Ratio
Day 4 -
Ratio
Day 5 -
Ratio
MEAN SD %CV
Negative
control
0.317 0.332 0.347 0.450 0.365 0.3622 0.0522 14.41%
Negative
control
0.328 0.328 0.325 0.399 0.355 0.347 0.0315 9.08%
Negative
control
0.257 0.328 0.332 0.383 0.329 0.3258 0.0449 13.78%
Positive
control
16.845 22.969 21.487 15.192 16.589 16.6164 3.3971 18.25%
Positive
control
18.506 22.969 17.776 19.038 19.579 19.5736 2.0116 10.28%
Positive
control
19.642 22.969 19.949 19.038 19.579 20.2354 1.563 7.72%
The %CV is detailed in the kit insert as follows for Inter Assay Reproducibility:
Negative 7.3%
Positive 3.5%
The %CV is detailed in the kit insert as follows for Inter Assay Repetitively:
Negative 17.3%
Positive 9.5%
The %CV obtained for all the negative samples should be between 7.3% and 17.3%. All three
negative control %CV was less than 17.3% and is acceptable. The OD value between each
negative sample over the 5 days was <30%, therefore Accuracy between each negative control
reading was good.
The %CV obtained for all the positive samples should be between 3.5% and 9.5%. Two of the three
positive control %CV was out of the acceptable range. The OD value between each positive sample
over the 5 days was <30%, therefore Accuracy between each positive control reading was good.
Sensitivity and Specificity testing:
50 known negative DBS samples and 42 known positive DBS samples were randomly selected and
tested on the Q-Preven assay. The result of the samples on the Q-Preven assay is 100% in
concordance with the initial NICD laboratory results. The sensitivity and specificity of the Q-Preven
Assay is listed below.
Sensitivity: 100%
Specificity: 100%
Negative Predictive Value: 100%
Positive Predictive Value: 100%
Replicate Testing - New Controls
Additional controls were tested.The lot numbers received were 2028200180 and 2028300180 for the
negative and the positive controls respectively. The negative and the positive controls were run 8
times in the same run and the results analyzed. All controls passed validation and all the controls
run as samples were within acceptable ranges i.e. the negative controls were negative and the
positive controls were positive.
The test method, calculation procedure, specifications of Validity and Interpretation of results was
taken from the Q-Preven Package insert Revision 3 – 28/12/2011
Limitations of Validation:
Specimens known to be positive or negative based on NICD test results were used.
There was no direct comparison testing between plasma/serum and dried blood spot testing to
assess performance of the kit.
Limited numbers of specimens were used for sensitivity and specificity to demonstrate that the
assay performed as expected.
General comment
The package insert although readable requires additional editing to ensure that there is no ambiguity
in terms of performing the assay.
Testing and Excel Spreadsheets done by: Ushmita Patel
Date: 28 December 2011
Report compiled by: Beverley Singh and Ushmita Patel
Date: 11 January 2012
Report Reviewed and Approved By: Prof Adrian J Puren
Date: 11 January 2012
Signature:
The report is not an endorsement or otherwise of the product.

Weitere ähnliche Inhalte

Ähnlich wie Validation of the Q - Preven HIV 1 2 DBS Immunoenzyme Kit REPORT FIN 11012012

Validation of anti niv igm capture elisa version#1
Validation of anti niv igm capture elisa version#1Validation of anti niv igm capture elisa version#1
Validation of anti niv igm capture elisa version#1krishgen
 
Trinity Uni Gold Hiv Presentation For Tx
Trinity Uni Gold Hiv Presentation For TxTrinity Uni Gold Hiv Presentation For Tx
Trinity Uni Gold Hiv Presentation For TxAdamHewitt
 
1.A new diagnostic test has been developed to Diagnose Disease.docx
1.A new diagnostic test has been developed to Diagnose Disease.docx1.A new diagnostic test has been developed to Diagnose Disease.docx
1.A new diagnostic test has been developed to Diagnose Disease.docxmansonagnus
 
Ab find, an antibody test after covid 19 vaccination by meril life
Ab find, an antibody test after covid 19 vaccination by meril lifeAb find, an antibody test after covid 19 vaccination by meril life
Ab find, an antibody test after covid 19 vaccination by meril lifeYashChopra43
 
Lupus Test - AVISE CTD Test Report Sample
Lupus Test - AVISE CTD Test Report SampleLupus Test - AVISE CTD Test Report Sample
Lupus Test - AVISE CTD Test Report SampleExagen Inc
 
Assay Standardisation - how this leads to improved patient results
Assay Standardisation - how this leads to improved patient resultsAssay Standardisation - how this leads to improved patient results
Assay Standardisation - how this leads to improved patient resultsWalt Whitman
 
Accuracy report of Healgen IgG/IgM Rapid Test kits Antibody
Accuracy report of Healgen IgG/IgM Rapid Test kits AntibodyAccuracy report of Healgen IgG/IgM Rapid Test kits Antibody
Accuracy report of Healgen IgG/IgM Rapid Test kits AntibodyHK HuZef
 
screening for diseases.pptx . ...
screening for diseases.pptx .             ...screening for diseases.pptx .             ...
screening for diseases.pptx . ...AkshayBadore2
 
report-Genrui-Antigen-Schnelltest-erstattungsfaehig-Bfarm-AT813-21-Profitest.pdf
report-Genrui-Antigen-Schnelltest-erstattungsfaehig-Bfarm-AT813-21-Profitest.pdfreport-Genrui-Antigen-Schnelltest-erstattungsfaehig-Bfarm-AT813-21-Profitest.pdf
report-Genrui-Antigen-Schnelltest-erstattungsfaehig-Bfarm-AT813-21-Profitest.pdfSchnelltestskaufen24.de
 
[BBBtech] portable infectious disease and inflammation test
[BBBtech] portable infectious disease and inflammation test[BBBtech] portable infectious disease and inflammation test
[BBBtech] portable infectious disease and inflammation testKyongsik Yun
 
Laboratory diagnosis of (hiv)
Laboratory diagnosis of  (hiv)Laboratory diagnosis of  (hiv)
Laboratory diagnosis of (hiv)abdulrahman amer
 
Epidemiological Approaches for Evaluation of diagnostic tests.pptx
Epidemiological Approaches for Evaluation of diagnostic tests.pptxEpidemiological Approaches for Evaluation of diagnostic tests.pptx
Epidemiological Approaches for Evaluation of diagnostic tests.pptxBhoj Raj Singh
 
Mihiret wachamo tesema 22525
Mihiret wachamo tesema 22525Mihiret wachamo tesema 22525
Mihiret wachamo tesema 22525NawarRizk1
 
A Fully Automated POCKIT Central PCR System for Evaluation of the Infectious ...
A Fully Automated POCKIT Central PCR System for Evaluation of the Infectious ...A Fully Automated POCKIT Central PCR System for Evaluation of the Infectious ...
A Fully Automated POCKIT Central PCR System for Evaluation of the Infectious ...Simon Chung - genereach
 
Using reference materials to meet validation & verification requirements for ...
Using reference materials to meet validation & verification requirements for ...Using reference materials to meet validation & verification requirements for ...
Using reference materials to meet validation & verification requirements for ...Candy Smellie
 
J. Clin. Microbiol.-2015-Gorton-JCM.00157-15
J. Clin. Microbiol.-2015-Gorton-JCM.00157-15J. Clin. Microbiol.-2015-Gorton-JCM.00157-15
J. Clin. Microbiol.-2015-Gorton-JCM.00157-15Rebecca Gorton
 
Lab diagnosis of syphilis
Lab diagnosis of syphilisLab diagnosis of syphilis
Lab diagnosis of syphilisHarsha Yaramati
 

Ähnlich wie Validation of the Q - Preven HIV 1 2 DBS Immunoenzyme Kit REPORT FIN 11012012 (20)

journal.pptx
journal.pptxjournal.pptx
journal.pptx
 
Validation of anti niv igm capture elisa version#1
Validation of anti niv igm capture elisa version#1Validation of anti niv igm capture elisa version#1
Validation of anti niv igm capture elisa version#1
 
Trinity Uni Gold Hiv Presentation For Tx
Trinity Uni Gold Hiv Presentation For TxTrinity Uni Gold Hiv Presentation For Tx
Trinity Uni Gold Hiv Presentation For Tx
 
Actualización sobre la producción de reactivos y pruebas comerciales disponib...
Actualización sobre la producción de reactivos y pruebas comerciales disponib...Actualización sobre la producción de reactivos y pruebas comerciales disponib...
Actualización sobre la producción de reactivos y pruebas comerciales disponib...
 
1.A new diagnostic test has been developed to Diagnose Disease.docx
1.A new diagnostic test has been developed to Diagnose Disease.docx1.A new diagnostic test has been developed to Diagnose Disease.docx
1.A new diagnostic test has been developed to Diagnose Disease.docx
 
Ab find, an antibody test after covid 19 vaccination by meril life
Ab find, an antibody test after covid 19 vaccination by meril lifeAb find, an antibody test after covid 19 vaccination by meril life
Ab find, an antibody test after covid 19 vaccination by meril life
 
Lupus Test - AVISE CTD Test Report Sample
Lupus Test - AVISE CTD Test Report SampleLupus Test - AVISE CTD Test Report Sample
Lupus Test - AVISE CTD Test Report Sample
 
Assay Standardisation - how this leads to improved patient results
Assay Standardisation - how this leads to improved patient resultsAssay Standardisation - how this leads to improved patient results
Assay Standardisation - how this leads to improved patient results
 
Accuracy report of Healgen IgG/IgM Rapid Test kits Antibody
Accuracy report of Healgen IgG/IgM Rapid Test kits AntibodyAccuracy report of Healgen IgG/IgM Rapid Test kits Antibody
Accuracy report of Healgen IgG/IgM Rapid Test kits Antibody
 
screening for diseases.pptx . ...
screening for diseases.pptx .             ...screening for diseases.pptx .             ...
screening for diseases.pptx . ...
 
report-Genrui-Antigen-Schnelltest-erstattungsfaehig-Bfarm-AT813-21-Profitest.pdf
report-Genrui-Antigen-Schnelltest-erstattungsfaehig-Bfarm-AT813-21-Profitest.pdfreport-Genrui-Antigen-Schnelltest-erstattungsfaehig-Bfarm-AT813-21-Profitest.pdf
report-Genrui-Antigen-Schnelltest-erstattungsfaehig-Bfarm-AT813-21-Profitest.pdf
 
[BBBtech] portable infectious disease and inflammation test
[BBBtech] portable infectious disease and inflammation test[BBBtech] portable infectious disease and inflammation test
[BBBtech] portable infectious disease and inflammation test
 
Moumita Ghosh OIST
Moumita Ghosh OIST Moumita Ghosh OIST
Moumita Ghosh OIST
 
Laboratory diagnosis of (hiv)
Laboratory diagnosis of  (hiv)Laboratory diagnosis of  (hiv)
Laboratory diagnosis of (hiv)
 
Epidemiological Approaches for Evaluation of diagnostic tests.pptx
Epidemiological Approaches for Evaluation of diagnostic tests.pptxEpidemiological Approaches for Evaluation of diagnostic tests.pptx
Epidemiological Approaches for Evaluation of diagnostic tests.pptx
 
Mihiret wachamo tesema 22525
Mihiret wachamo tesema 22525Mihiret wachamo tesema 22525
Mihiret wachamo tesema 22525
 
A Fully Automated POCKIT Central PCR System for Evaluation of the Infectious ...
A Fully Automated POCKIT Central PCR System for Evaluation of the Infectious ...A Fully Automated POCKIT Central PCR System for Evaluation of the Infectious ...
A Fully Automated POCKIT Central PCR System for Evaluation of the Infectious ...
 
Using reference materials to meet validation & verification requirements for ...
Using reference materials to meet validation & verification requirements for ...Using reference materials to meet validation & verification requirements for ...
Using reference materials to meet validation & verification requirements for ...
 
J. Clin. Microbiol.-2015-Gorton-JCM.00157-15
J. Clin. Microbiol.-2015-Gorton-JCM.00157-15J. Clin. Microbiol.-2015-Gorton-JCM.00157-15
J. Clin. Microbiol.-2015-Gorton-JCM.00157-15
 
Lab diagnosis of syphilis
Lab diagnosis of syphilisLab diagnosis of syphilis
Lab diagnosis of syphilis
 

Mehr von Terra Vivos

VivosSouthAmerica
VivosSouthAmericaVivosSouthAmerica
VivosSouthAmericaTerra Vivos
 
vivossurvivalreport
vivossurvivalreportvivossurvivalreport
vivossurvivalreportTerra Vivos
 
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMO
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMOAPRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMO
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMOTerra Vivos
 
Apresentação Prime - INGLÊS - programa de triagem (10) ALTERAÇÕES1.ppt (1.103)
Apresentação Prime - INGLÊS - programa de triagem   (10) ALTERAÇÕES1.ppt (1.103)Apresentação Prime - INGLÊS - programa de triagem   (10) ALTERAÇÕES1.ppt (1.103)
Apresentação Prime - INGLÊS - programa de triagem (10) ALTERAÇÕES1.ppt (1.103)Terra Vivos
 
Reflecting on brazil’s success how durable what lessons for south africa
Reflecting on brazil’s success how durable what lessons for south africaReflecting on brazil’s success how durable what lessons for south africa
Reflecting on brazil’s success how durable what lessons for south africaTerra Vivos
 
Consultancy activities andrã© s.efstathiou
Consultancy activities andrã© s.efstathiouConsultancy activities andrã© s.efstathiou
Consultancy activities andrã© s.efstathiouTerra Vivos
 
Q preven elisa.marketing..march 2012
Q preven elisa.marketing..march 2012Q preven elisa.marketing..march 2012
Q preven elisa.marketing..march 2012Terra Vivos
 
Company formation ..directives
Company formation ..directivesCompany formation ..directives
Company formation ..directivesTerra Vivos
 
Professional profile ase review
Professional profile ase reviewProfessional profile ase review
Professional profile ase reviewTerra Vivos
 
Sales Projection --Bio Oxford
Sales Projection --Bio OxfordSales Projection --Bio Oxford
Sales Projection --Bio OxfordTerra Vivos
 
Revista new lab artigo 6 inglês
Revista new lab artigo 6 inglêsRevista new lab artigo 6 inglês
Revista new lab artigo 6 inglêsTerra Vivos
 
Prime diagnostics
Prime diagnosticsPrime diagnostics
Prime diagnosticsTerra Vivos
 
Apresentação prime 092009_ing
Apresentação prime 092009_ingApresentação prime 092009_ing
Apresentação prime 092009_ingTerra Vivos
 

Mehr von Terra Vivos (14)

VivosSouthAmerica
VivosSouthAmericaVivosSouthAmerica
VivosSouthAmerica
 
vivossurvivalreport
vivossurvivalreportvivossurvivalreport
vivossurvivalreport
 
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMO
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMOAPRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMO
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMO
 
Apresentação Prime - INGLÊS - programa de triagem (10) ALTERAÇÕES1.ppt (1.103)
Apresentação Prime - INGLÊS - programa de triagem   (10) ALTERAÇÕES1.ppt (1.103)Apresentação Prime - INGLÊS - programa de triagem   (10) ALTERAÇÕES1.ppt (1.103)
Apresentação Prime - INGLÊS - programa de triagem (10) ALTERAÇÕES1.ppt (1.103)
 
Reflecting on brazil’s success how durable what lessons for south africa
Reflecting on brazil’s success how durable what lessons for south africaReflecting on brazil’s success how durable what lessons for south africa
Reflecting on brazil’s success how durable what lessons for south africa
 
Consultancy activities andrã© s.efstathiou
Consultancy activities andrã© s.efstathiouConsultancy activities andrã© s.efstathiou
Consultancy activities andrã© s.efstathiou
 
Q preven elisa.marketing..march 2012
Q preven elisa.marketing..march 2012Q preven elisa.marketing..march 2012
Q preven elisa.marketing..march 2012
 
Company formation ..directives
Company formation ..directivesCompany formation ..directives
Company formation ..directives
 
Professional profile ase review
Professional profile ase reviewProfessional profile ase review
Professional profile ase review
 
Sales Projection --Bio Oxford
Sales Projection --Bio OxfordSales Projection --Bio Oxford
Sales Projection --Bio Oxford
 
Revista new lab artigo 6 inglês
Revista new lab artigo 6 inglêsRevista new lab artigo 6 inglês
Revista new lab artigo 6 inglês
 
Prime diagnostics
Prime diagnosticsPrime diagnostics
Prime diagnostics
 
Apresentação prime 092009_ing
Apresentação prime 092009_ingApresentação prime 092009_ing
Apresentação prime 092009_ing
 
Bio Oxford
Bio OxfordBio Oxford
Bio Oxford
 

Validation of the Q - Preven HIV 1 2 DBS Immunoenzyme Kit REPORT FIN 11012012

  • 1. OFFICE OF THE DEPUTY DIRECTOR VIROLOGY NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES 1 Modderfontein Road, Sandringham, 2031 Tel: +27 (0)11 386-6328 Fax: +27 (0)11 386-6411 Validation of the Q – Preven HIV 1 + 2 DBS Immunoenzyme Kit Summary: The Q-Preven HIV 1+2 DBS kit is an enzyme immunosorbent assay (ELISA) for the detection of antibodies against HIV 1, HIV 2 and HIV 1 subtype O in Dried Blood Spot Specimens (DBS). The kit consists of the following items: Dried Blood Spot Collection Kit which consists of the filter paper and lancet; and the Test Kit which consists of ELISA Microplate and ELISA reagents required to conduct an ELISA test. Supplies with the kit are negative and positive dried blood spot controls. The following steps were completed during the validation: Replicate testing using Kit Controls: The negative DBS control and the positive DBS control from the Q-Preven test kit was tested 8 times in the same run and the results analyzed. All the controls passed validation and all controls run as samples were within acceptable ranges i.e. the negative controls were negative and the positive controls were positive. Precision and Accuracy Testing: Three negative and three positive controls taken from the Q-Preven test kit were tested over a period of five consecutive days. The same operator tested the controls over the five day period and the same plate washer, plate incubator and plate reader was used during the testing. The results of the precision and accuracy testing are listed in Table 1 below:
  • 2. Table 1 ID Day 1 - Ratio Day 2 - Ratio Day 3 - Ratio Day 4 - Ratio Day 5 - Ratio MEAN SD %CV Negative control 0.317 0.332 0.347 0.450 0.365 0.3622 0.0522 14.41% Negative control 0.328 0.328 0.325 0.399 0.355 0.347 0.0315 9.08% Negative control 0.257 0.328 0.332 0.383 0.329 0.3258 0.0449 13.78% Positive control 16.845 22.969 21.487 15.192 16.589 16.6164 3.3971 18.25% Positive control 18.506 22.969 17.776 19.038 19.579 19.5736 2.0116 10.28% Positive control 19.642 22.969 19.949 19.038 19.579 20.2354 1.563 7.72% The %CV is detailed in the kit insert as follows for Inter Assay Reproducibility: Negative 7.3% Positive 3.5% The %CV is detailed in the kit insert as follows for Inter Assay Repetitively: Negative 17.3% Positive 9.5%
  • 3. The %CV obtained for all the negative samples should be between 7.3% and 17.3%. All three negative control %CV was less than 17.3% and is acceptable. The OD value between each negative sample over the 5 days was <30%, therefore Accuracy between each negative control reading was good. The %CV obtained for all the positive samples should be between 3.5% and 9.5%. Two of the three positive control %CV was out of the acceptable range. The OD value between each positive sample over the 5 days was <30%, therefore Accuracy between each positive control reading was good. Sensitivity and Specificity testing: 50 known negative DBS samples and 42 known positive DBS samples were randomly selected and tested on the Q-Preven assay. The result of the samples on the Q-Preven assay is 100% in concordance with the initial NICD laboratory results. The sensitivity and specificity of the Q-Preven Assay is listed below. Sensitivity: 100% Specificity: 100% Negative Predictive Value: 100% Positive Predictive Value: 100% Replicate Testing - New Controls Additional controls were tested.The lot numbers received were 2028200180 and 2028300180 for the negative and the positive controls respectively. The negative and the positive controls were run 8 times in the same run and the results analyzed. All controls passed validation and all the controls run as samples were within acceptable ranges i.e. the negative controls were negative and the positive controls were positive.
  • 4. The test method, calculation procedure, specifications of Validity and Interpretation of results was taken from the Q-Preven Package insert Revision 3 – 28/12/2011 Limitations of Validation: Specimens known to be positive or negative based on NICD test results were used. There was no direct comparison testing between plasma/serum and dried blood spot testing to assess performance of the kit. Limited numbers of specimens were used for sensitivity and specificity to demonstrate that the assay performed as expected. General comment The package insert although readable requires additional editing to ensure that there is no ambiguity in terms of performing the assay. Testing and Excel Spreadsheets done by: Ushmita Patel Date: 28 December 2011 Report compiled by: Beverley Singh and Ushmita Patel Date: 11 January 2012 Report Reviewed and Approved By: Prof Adrian J Puren Date: 11 January 2012 Signature: The report is not an endorsement or otherwise of the product.